by The global Epigenetics Market is estimated to be valued at US$ 14.80 Bn in 2023 and is expected to exhibit a CAGR of 1.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview: Epigenetics involves the study of heritable changes in gene expression or cellular phenotype that do not involve alterations to the DNA sequence. This branch of genetics allows scientists to further understand genome functions and interactions between genes and environment. Advances in epigenetics technology are helping target therapeutics for various diseases like cancer.
Market key trends: One of the key trends in the epigenetics market is growing applications of epigenetics technology in digital health. Developments in epigenetic biomarkers and high-throughput sequencing technologies are allowing digital integration of epigenetic data. This is supporting early disease detection and real-time tracking of therapeutic responses in cancer and other chronic illnesses. Companies are focusing on developing epigenetic-based digital tools and apps for personalized medicine and telehealth. For instance, Anthropic has developed an AI tool called PBC that maps epigenetic changes and gene expression patterns associated with cancers and development disorders.
Segment Analysis
The Global Epigenetics Market is dominated by the kits and reagents sub-segment. This sub-segment holds the largest market share due to the continuously increasing number of epigenetics-based research activities and clinical diagnostic procedures that require various kits and reagents. The kits and reagents sub-segment facilitates research activities including DNA modification detection, chip-based/high-throughput analysis, and large-scale Bisulfite sequencing.
Key Takeaways
The global epigenetics market is expected to witness high growth, exhibiting a CAGR of 1.0% over the forecast period, due to continuously increasing investments in epigenetics research and rising prevalence of cancer and other chronic diseases.
The North American region accounts for the largest share in the epigenetics market owing to continuous government funding to support epigenetics research in the region. However, the Asia Pacific region is expected to witness the fastest growth rate over the forecast period owing to increasing R&D activities, favourable government policies, and significant developments in the field of epigenetics.
Key players operating in the epigenetics market are Active Motif, Inc., Zymo Research, Thermo Fisher Scientific Inc., QIAGEN N.V., Merck Millipore, Illumina Inc., Agilent Technologies, Inc., Abcam Plc., Hologic Inc., and PerkinElmer, Inc. Thermo Fisher Scientific Inc. is currently the dominant player in the global epigenetics market. It offers a wide range of innovative epigenetics products and services, including reagents, kits, instruments, and software. In October 2022, Thermo Fisher Scientific launched new epigenetics panels and controls to advance precision oncology research.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
